- Psychiatry - Research Publications
Psychiatry - Research Publications
Permanent URI for this collection
Search Results
Now showing
1 - 10 of 2505
-
ItemNo Preview AvailableA preliminary investigation of the clinical and cognitive correlates of circulating vitamin D in bipolar disorderVan Rheenen, TE ; Ringin, E ; Karantonis, JA ; Furlong, L ; Bozaoglu, K ; Rossell, SL ; Berk, M ; Balanza-Martinez, V (ELSEVIER IRELAND LTD, 2022-12-21)The role that vitamin D plays in the cognitive and clinical characteristics of bipolar disorder (BD) is unclear. We examined differences in the levels and deficiency status of vitamin D in an Australian sample of BD patients compared to healthy controls; and determined the extent to which vitamin D is associated with clinical variables and cognitive function in the sample. 22 healthy controls and 55 stable outpatients with a diagnosis of BD and low-grade mood symptomatology provided a sample of blood and completed cognitive tests and clinical measures. Plasma concentrations of 25-hydroxyvitamin D (vitamin D) were assayed and used to segregate participants into subgroups with sufficient or deficient levels of vitamin D. Subgroups were then compared in terms of global cognition and a range of sociodemographic and clinical factors (number of past mood episodes, illness duration, seasonal mood pattern, mood symptom severity), while mean levels of vitamin D were compared between patients and controls. Although almost 27% of the current sample were vitamin D deficient, no significant differences in mean vitamin D levels or the prevalence of vitamin D deficiency were evident between BD patients and controls. Vitamin D was not associated with global cognition in either patients or controls, nor any of the clinical measures assessed in the study. In conclusion, we observed no difference in the vitamin D levels and deficiency status of an Australian sample of healthy individuals and BD patients with low grade mood symptomatology compared to controls. Clinical symptoms and global cognition also appear to be independent of vitamin D levels in BD.
-
ItemStakeholder input into the implementation of a new music therapy program in a mental health serviceBibb, J ; Castle, D ; McFerran, KS (Emerald, 2018-01-01)Purpose: Music therapy programs are increasingly common and necessary in mental health services. However, there is little knowledge of the key factors which influence the successful implementation of new therapeutic programs. The purpose of this paper is to explore how stakeholder input influenced the implementation and sustainability of a new music therapy program in four services within a large government funded mental health department in Melbourne, Australia. Design/methodology/approach: For a period of 12 months, two cycles of assessment, action and evaluation were conducted where data were collected through interviews with staff members, feedback from consumers and attendance in sessions. Findings: A number of influential factors were identified as important in the successful implementation and future sustainability of the music therapy program. These included: the degree of staff support received; how the program was structured and facilitated; promotion of the program within the service; evaluation of the program; and congruence with the existing therapeutic program. Research limitations/implications: Results suggest that successful implementation and future sustainability of a music therapy program is dependent on the flexibility of the program to the context and culture of the existing setting. Originality/value: This is the first study to incorporate contributions from stakeholders in the implementation of a new music therapy program in a mental health service.
-
ItemBrain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium.Constantinides, C ; Han, LKM ; Alloza, C ; Antonucci, LA ; Arango, C ; Ayesa-Arriola, R ; Banaj, N ; Bertolino, A ; Borgwardt, S ; Bruggemann, J ; Bustillo, J ; Bykhovski, O ; Calhoun, V ; Carr, V ; Catts, S ; Chung, Y-C ; Crespo-Facorro, B ; Díaz-Caneja, CM ; Donohoe, G ; Plessis, SD ; Edmond, J ; Ehrlich, S ; Emsley, R ; Eyler, LT ; Fuentes-Claramonte, P ; Georgiadis, F ; Green, M ; Guerrero-Pedraza, A ; Ha, M ; Hahn, T ; Henskens, FA ; Holleran, L ; Homan, S ; Homan, P ; Jahanshad, N ; Janssen, J ; Ji, E ; Kaiser, S ; Kaleda, V ; Kim, M ; Kim, W-S ; Kirschner, M ; Kochunov, P ; Kwak, YB ; Kwon, JS ; Lebedeva, I ; Liu, J ; Mitchie, P ; Michielse, S ; Mothersill, D ; Mowry, B ; de la Foz, VO-G ; Pantelis, C ; Pergola, G ; Piras, F ; Pomarol-Clotet, E ; Preda, A ; Quidé, Y ; Rasser, PE ; Rootes-Murdy, K ; Salvador, R ; Sangiuliano, M ; Sarró, S ; Schall, U ; Schmidt, A ; Scott, RJ ; Selvaggi, P ; Sim, K ; Skoch, A ; Spalletta, G ; Spaniel, F ; Thomopoulos, SI ; Tomecek, D ; Tomyshev, AS ; Tordesillas-Gutiérrez, D ; van Amelsvoort, T ; Vázquez-Bourgon, J ; Vecchio, D ; Voineskos, A ; Weickert, CS ; Weickert, T ; Thompson, PM ; Schmaal, L ; van Erp, TGM ; Turner, J ; Cole, JH ; ENIGMA Schizophrenia Consortium, ; Dima, D ; Walton, E (Springer Science and Business Media LLC, 2023-03)Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18-72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18-73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19; I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen's d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions.
-
ItemPlasma Neurofilament Light Chain and Clinical Diagnosis in Frontotemporal Dementia SyndromesOoi, S ; Patel, SK ; Eratne, D ; Kyndt, C ; Reidy, N ; Lewis, C ; Lee, SCM ; Darby, D ; Brodtmann, A (IOS PRESS, 2022-01-01)BACKGROUND: Frontotemporal dementia (FTD) syndromes, mimics, phenocopy (phFTD), and slowly progressive behavioral variant FTD (bvFTD) can be difficult to distinguish clinically. Biomarkers such as neurofilament light chain (NfL) may be helpful. OBJECTIVE: To study plasma NfL levels in people with FTD syndromes and determine if plasma NfL can distinguish between FTD syndromes and phFTD. METHODS: Plasma NfL levels were estimated using both Simoa® Quanterix HD-X™ and SR-X™ machines grouped via final diagnosis after investigation and review. RESULTS: Fifty participants were studied: bvFTD = 20, semantic variant FTD (svFTD) = 11, non-fluent variant FTD (nfvFTD) = 9, FTD with motor neuron disease (MND) = 4, phFTD = 2, slow progressors = 3, FTD mimic = 1, mean age 67.2 (SD 8.4) years. NfL levels were significantly higher in the FTD group compared to phenocopy group (p = 0.003). Median NfL (IQR) pg/mL was comparable in the FTD syndromes: bvFTD 41.10 (50.72), svFTD 44.38 (16.61), and nfvFTD 42.61 (22.93), highest in FTD with MND 79.67 (45.32) and lowest in both phFTD 13.99 (0.79) and slow progressors 17.97 (3.62). CONCLUSION: Plasma NfL appears to differentiate FTD syndromes and mimics. However, a lower NfL may predict a slower, but not necessarily absence of neurodegeneration, and therefore appears limited in distinguishing slow progressors from FTD phenocopies. Larger numbers of patients from all clinical groups are required to strengthen diagnostic utility.
-
ItemClinical guidelines for the use of lifestyle-based mental health care in major depressive disorder: World Federation of Societies for Biological Psychiatry (WFSBP) and Australasian Society of Lifestyle Medicine (ASLM) taskforceMarx, W ; Manger, SH ; Blencowe, M ; Murray, G ; Ho, FY-Y ; Lawn, S ; Blumenthal, JA ; Schuch, F ; Stubbs, B ; Ruusunen, A ; Desyibelew, HD ; Dinan, TG ; Jacka, F ; Ravindran, A ; Berk, M ; O'Neil, A (TAYLOR & FRANCIS LTD, 2022-09-20)OBJECTIVES: The primary objectives of these international guidelines were to provide a global audience of clinicians with (a) a series of evidence-based recommendations for the provision of lifestyle-based mental health care in clinical practice for adults with Major Depressive Disorder (MDD) and (b) a series of implementation considerations that may be applicable across a range of settings. METHODS: Recommendations and associated evidence-based gradings were based on a series of systematic literature searches of published research as well as the clinical expertise of taskforce members. The focus of the guidelines was eight lifestyle domains: physical activity and exercise, smoking cessation, work-directed interventions, mindfulness-based and stress management therapies, diet, sleep, loneliness and social support, and green space interaction. The following electronic bibliographic databases were searched for articles published prior to June 2020: PubMed, EMBASE, The Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Methodology Register), CINAHL, PsycINFO. Evidence grading was based on the level of evidence specific to MDD and risk of bias, in accordance with the World Federation of Societies for Biological Psychiatry criteria. RESULTS: Nine recommendations were formed. The recommendations with the highest ratings to improve MDD were the use of physical activity and exercise, relaxation techniques, work-directed interventions, sleep, and mindfulness-based therapies (Grade 2). Interventions related to diet and green space were recommended, but with a lower strength of evidence (Grade 3). Recommendations regarding smoking cessation and loneliness and social support were based on expert opinion. Key implementation considerations included the need for input from allied health professionals and support networks to implement this type of approach, the importance of partnering such recommendations with behaviour change support, and the need to deliver interventions using a biopsychosocial-cultural framework. CONCLUSIONS: Lifestyle-based interventions are recommended as a foundational component of mental health care in clinical practice for adults with Major Depressive Disorder, where other evidence-based therapies can be added or used in combination. The findings and recommendations of these guidelines support the need for further research to address existing gaps in efficacy and implementation research, especially for emerging lifestyle-based approaches (e.g. green space, loneliness and social support interventions) where data are limited. Further work is also needed to develop innovative approaches for delivery and models of care, and to support the training of health professionals regarding lifestyle-based mental health care.
-
ItemLifetime and current depression in the German National Cohort (NAKO).Streit, F ; Zillich, L ; Frank, J ; Kleineidam, L ; Wagner, M ; Baune, BT ; Klinger-König, J ; Grabe, HJ ; Pabst, A ; Riedel-Heller, SG ; Schmiedek, F ; Schmidt, B ; Erhardt, A ; Deckert, J ; NAKO Investigators, ; Rietschel, M ; Berger, K (Informa UK Limited, 2022-02-17)OBJECTIVES: The present study introduces the assessment of depression and depressive symptoms in the German National Cohort (NAKO), a population-based mega cohort. Distribution of core measures, and associations with sociodemographic factors are examined. METHODS: The current analysis includes data from the first 101,667 participants (NAKO data freeze 100,000). Depression and depressive symptoms were assessed using a modified version of the depression section of the Mini-International Neuropsychiatric Interview (MINI), self-reported physician's diagnosis of depression, and the depression scale of the Patient Health Questionnaire (PHQ-9). RESULTS: A lifetime physician's diagnosis of depression was reported by 15.0% of participants. Of those, 47.6% reported having received treatment for depression within the last 12 months. Of the subset of 26,342 participants undergoing the full depression section of the modified MINI, 15.9% were classified by the MINI with a lifetime depressive episode. Based on the PHQ-9, 5.8% of the participants were classified as currently having a major or other depression by the diagnostic algorithm, and 7.8% according to the dimensional assessment (score ≥ 10). Increased frequency of depression measures and higher depression scores were observed in women and participants with lower education level or a family history of depression. CONCLUSIONS: The observed distributions of all depression measures and their associations with sociodemographic variables are consistent with the literature on depression. The NAKO represents a valuable epidemiologic resource to investigate depression, and the range of measures for lifetime and current depression allows users to select the most suitable instrument for their specific research question.
-
ItemClinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) TaskforceSarris, J ; Ravindran, A ; Yatham, LN ; Marx, W ; Rucklidge, JJ ; McIntyre, RS ; Akhondzadeh, S ; Benedetti, F ; Caneo, C ; Cramer, H ; Cribb, L ; de Manincor, M ; Dean, O ; Deslandes, AC ; Freeman, MP ; Gangadhar, B ; Harvey, BH ; Kasper, S ; Lake, J ; Lopresti, A ; Lu, L ; Metri, N-J ; Mischoulon, D ; Ng, CH ; Nishi, D ; Rahimi, R ; Seedat, S ; Sinclair, J ; Su, K-P ; Zhang, Z-J ; Berk, M (TAYLOR & FRANCIS LTD, 2022-03-16)OBJECTIVES: The therapeutic use of nutrient-based 'nutraceuticals' and plant-based 'phytoceuticals' for the treatment of mental disorders is common; however, despite recent research progress, there have not been any updated global clinical guidelines since 2015. To address this, the World Federation of Societies of Biological Psychiatry (WFSBP) and the Canadian Network for Mood and Anxiety Disorders (CANMAT) convened an international taskforce involving 31 leading academics and clinicians from 15 countries, between 2019 and 2021. These guidelines are aimed at providing a definitive evidence-informed approach to assist clinicians in making decisions around the use of such agents for major psychiatric disorders. We also provide detail on safety and tolerability, and clinical advice regarding prescription (e.g. indications, dosage), in addition to consideration for use in specialised populations. METHODS: The methodology was based on the WFSBP guidelines development process. Evidence was assessed based on the WFSBP grading of evidence (and was modified to focus on Grade A level evidence - meta-analysis or two or more RCTs - due to the breadth of data available across all nutraceuticals and phytoceuticals across major psychiatric disorders). The taskforce assessed both the 'level of evidence' (LoE) (i.e. meta-analyses or RCTs) and the assessment of the direction of the evidence, to determine whether the intervention was 'Recommended' (+++), 'Provisionally Recommended' (++), 'Weakly Recommended' (+), 'Not Currently Recommended' (+/-), or 'Not Recommended' (-) for a particular condition. Due to the number of clinical trials now available in the field, we firstly examined the data from our two meta-reviews of meta-analyses (nutraceuticals conducted in 2019, and phytoceuticals in 2020). We then performed a search of additional relevant RCTs and reported on both these data as the primary drivers supporting our clinical recommendations. Lower levels of evidence, including isolated RCTs, open label studies, case studies, preclinical research, and interventions with only traditional or anecdotal use, were not assessed. RESULTS: Amongst nutraceuticals with Grade A evidence, positive directionality and varying levels of support (recommended, provisionally recommended, or weakly recommended) was found for adjunctive omega-3 fatty acids (+++), vitamin D (+), adjunctive probiotics (++), adjunctive zinc (++), methylfolate (+), and adjunctive s-adenosyl methionine (SAMe) (+) in the treatment of unipolar depression. Monotherapy omega-3 (+/-), folic acid (-), vitamin C (-), tryptophan (+/-), creatine (+/-), inositol (-), magnesium (-), and n-acetyl cysteine (NAC) (+/-) and SAMe (+/-) were not supported for this use. In bipolar disorder, omega-3 had weak support for bipolar depression (+), while NAC was not currently recommended (+/-). NAC was weakly recommended (+) in the treatment of OCD-related disorders; however, no other nutraceutical had sufficient evidence in any anxiety-related disorder. Vitamin D (+), NAC (++), methylfolate (++) were recommended to varying degrees in the treatment of the negative symptoms in schizophrenia, while omega-3 fatty acids were not, although evidence suggests a role for prevention of transition to psychosis in high-risk youth, with potential pre-existing fatty acid deficiency. Micronutrients (+) and vitamin D (+) were weakly supported in the treatment of ADHD, while omega-3 (+/-) and omega-9 fatty acids (-), acetyl L carnitine (-), and zinc (+/-) were not supported. Phytoceuticals with supporting Grade A evidence and positive directionality included St John's wort (+++), saffron (++), curcumin (++), and lavender (+) in the treatment of unipolar depression, while rhodiola use was not supported for use in mood disorders. Ashwagandha (++), galphimia (+), and lavender (++) were modestly supported in the treatment of anxiety disorders, while kava (-) and chamomile (+/-) were not recommended for generalised anxiety disorder. Ginkgo was weakly supported in the adjunctive treatment of negative symptoms of schizophrenia (+), but not supported in the treatment of ADHD (+/-). With respect to safety and tolerability, all interventions were deemed to have varying acceptable levels of safety and tolerability for low-risk over-the-counter use in most circumstances. Quality and standardisation of phytoceuticals was also raised by the taskforce as a key limiting issue for firmer confidence in these agents. Finally, the taskforce noted that such use of nutraceuticals or phytoceuticals be primarily recommended (where supportive evidence exists) adjunctively within a standard medical/health professional care model, especially in cases of more severe mental illness. Some meta-analyses reviewed contained data from heterogenous studies involving poor methodology. Isolated RCTs and other data such as open label or case series were not included, and it is recognised that an absence of data does not imply lack of efficacy. CONCLUSIONS: Based on the current data and clinician input, a range of nutraceuticals and phytoceuticals were given either a supportive recommendation or a provisional recommendation across a range of various psychiatric disorders. However several had only a weak endorsement for potential use; for a few it was not possible to reach a clear recommendation direction, largely due to mixed study findings; while some other agents showed no obvious therapeutic benefit and were clearly not recommended for use. It is the intention of these guidelines to inform psychiatric/medical, and health professional practice globally.
-
ItemOlder adults' experiences of a computerised cognitive training intervention: a mixed methods studyTrenorden, K ; Hull, MJ ; Lampit, A ; Greaves, D ; Keage, HAD (TAYLOR & FRANCIS LTD, 2022-12-31)
-
ItemNeoliberal Hegemonic Masculinity and McMindfulness: The Need for Buddhist Values and Principles in Mindful Masculinity ProgramsForbes, D (MDPI AG, 2022-06-01)This paper explores how certain Buddhist-inspired principles such as impermanence of self and compassion for all (metta) and the practice of mindfulness can contribute to challenging ways in which young men adopt troublesome aspects of systemic patriarchy. It (1) briefly examines the problem of systemic patriarchy in its most dominant forms, neoliberal hegemonic masculinity and right-wing racist authoritarian masculinity; (2) critically discusses examples of mindfulness education and counseling programs for young men that have been severed from their Buddhist origins (McMindfulness) that attempt to challenge young men around patriarchal beliefs and thoughts but end up reproducing neoliberal hegemonic masculinity; (3) briefly considers the problem of McMindfulness and its relation to Buddhism and neoliberal hegemonic and mindful masculinity; and (4) offers Buddhist perspectives as part of a counter-view that may serve within programs as an alternative to current forms of patriarchy while including and renewing the aforementioned Buddhist principles.
-
ItemThe Potential Impact of a Public Health Approach to Improving the Physical Health of People Living with Mental IllnessRoberts, R ; Johnson, C ; Hopwood, M ; Firth, J ; Jackson, K ; Sara, G ; Allan, J ; Calder, R ; Manger, S (MDPI, 2022-09-01)With already wide disparities in physical health and life expectancy, COVID-19 presents people with mental illness with additional threats to their health: decreased access to health services, increased social isolation, and increased socio-economic disadvantage. Each of these factors has exacerbated the risk of poor health and early death for people with mental illness post-COVID-19. Unless effective primary care and preventative health responses are implemented, the physical illness epidemic for this group will increase post the COVID-19 pandemic. This perspective paper briefly reviews the literature on the impact of COVID-19 on service access, social isolation, and social disadvantage and their combined impact on physical health, particularly cancer, respiratory diseases, heart disease, smoking, and infectious diseases. The much-overlooked role of poor physical health on suicidality is also discussed. The potential impact of public health interventions is modelled based on Australian incidence data and current research on the percentage of early deaths of people living with mental illnesses that are preventable. Building on the lessons arising from services' response to COVID-19, such as the importance of ensuring access to preventive, screening, and primary care services, priority recommendations for consideration by public health practitioners and policymakers are presented.